エピソード

  • Tanzania TMDA Medical Device Registration Fees 2027: Key Deadlines

    Tanzania TMDA Medical Device Registration Fees 2027: Key Deadlines
    2026/11/05
    The Tanzania Medicines and Medical Devices Authority (TMDA) has announced its annual retention fee schedule for 2027, introducing critical deadlines that medical device manufacturers must meet to maintain market access. This episode details the multi-stage process, starting with the mandatory continued-marketing declaration due by November 1, 2026. We break down the fee structure—USD 200 per registered device and USD 50 per notified device—and the final payment deadline of January 31, 2027. We also explain the severe consequences of non-compliance, including registration suspension and import permit blocks, which take effect from April 1, 2027. Tune in for practical steps your team can take now to prepare for these requirements and avoid costly disruptions to your business in Tanzania. Key Questions: - What are the key deadlines for Tanzania's 2027 medical device retention fees? - How much are the annual fees for registered and notified medical devices in Tanzania? - What is the continued-marketing declaration and why is the November 1, 2026 deadline so important? - What happens if manufacturers miss the TMDA's payment deadline of January 31, 2027? - Why is the April 1, 2027 date critical for maintaining market access in Tanzania? - What immediate steps should regulatory teams take to prepare for these requirements? - How can companies avoid registration suspension and import permit blocks for their devices? - What are the financial and logistical implications of TMDA's 2027 fee schedule for manufacturers? - How should companies coordinate with their local Tanzanian representatives for this process? Sources: - https://pureglobal.com/news/medical-device-regulatory-news-and-updates/ How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech companies access and maintain their presence in over 30 global markets, including Tanzania. Our local experts can act as your in-country representative, manage submission of declarations, and ensure timely fee payments to authorities like the TMDA. We leverage advanced AI and data tools to develop efficient regulatory strategies, compile technical dossiers, and monitor changes that impact your registrations. Whether you need to manage annual renewals or expand into new markets, Pure Global streamlines the process. Visit us at https://pureglobal.com, contact us at info@pureglobal.com, or explore our free regulatory AI tools and device database at https://pureglobal.ai.
    続きを読む 一部表示
    5 分
  • Brazil ANVISA Recognized Technical Standards: New Lists for Orthopedic and Health-Use Materials

    Brazil ANVISA Recognized Technical Standards: New Lists for Orthopedic and Health-Use Materials
    2026/11/04
    On October 22, 2026, Brazil's ANVISA released three workbooks of recognized technical standards impacting medical device manufacturers. This episode details the contents of the new "Transversal Standards" (v1.0) and "Health-Use Materials" (v0.0) lists, as well as the updated "Orthopedic Implantable Materials" (v1.1) list. We explain how voluntary compliance with these standards can create a presumption of conformity, potentially streamlining the review of technical dossiers. We cover which device categories are affected and provide practical steps for regulatory teams to perform a gap analysis and update their submission strategies for the Brazilian market. Key Questions: - What are the three new technical standard lists ANVISA published on October 22, 2026? - How do these recognized standards impact the review process for medical device submissions in Brazil? - Which specific device types are affected by the new lists for orthopedic and health-use materials? - What is the significance of the new "transversal standards" list for all device manufacturers? - Is compliance with these ANVISA-recognized standards mandatory? - How can referencing these standards streamline your technical dossier preparation? - What practical steps should your regulatory team take in response to these updates? - Why is it important to monitor these ANVISA workbooks for future versions? Sources: - https://www.pure-global.com/insights/anvisa-publishes-three-recognized-device-standards-lists How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech companies access global markets faster. Our experts can help you navigate complex regulatory changes, such as ANVISA's new recognized technical standards, by developing a clear market access strategy, performing gap analyses, and compiling robust technical dossiers that meet local requirements. With a presence in over 30 countries, we act as your local representative and ensure ongoing compliance. Visit us at https://pureglobal.com or contact us at info@pureglobal.com. Explore our free AI regulatory tools and global device database at https://pureglobal.ai to streamline your research and submissions.
    続きを読む 一部表示
    5 分
  • South Korea MFDS Proposes 'One-Stop' Certification for Class II Medical Devices

    South Korea MFDS Proposes 'One-Stop' Certification for Class II Medical Devices
    2026/11/03
    South Korea's Ministry of Food and Drug Safety (MFDS) has proposed a significant amendment to streamline the certification process for Class II medical devices. This episode details the new 'one-stop' pathway, which combines the technical document review and certification application into a single, simultaneous submission to the National Institute of Medical Device Safety Information (NIDS). We explore how this change is expected to reduce the total processing time from approximately 40 days to 25 days and offer practical advice for manufacturers to prepare for this accelerated market access route following the closure of the public comment period on October 26, 2026. Key Questions: - What is South Korea's MFDS proposing for Class II medical device certification? - How does the new 'one-stop' process differ from the current sequential system? - What is the expected reduction in review time for Class II devices? - What is the role of the National Institute of Medical Device Safety Information (NIDS) in the new process? - When did the public comment period for this proposed amendment close? - How can manufacturers prepare their technical documentation for this potential change? - Why is a complete and accurate initial submission more critical under a simultaneous review process? - What practical steps should regulatory teams take to leverage this accelerated pathway? - How could this change impact market entry timelines and commercial strategy? Sources: - https://www.gca-korea.com/post/korean-mfds-to-introduce-a-one-stop-certification-and-review-process-for-class-ii-medical-devices - https://www.youtube.com/watch?v=example_placeholder_for_25 How Pure Global can help: Pure Global streamlines global market access for MedTech and IVD companies. For South Korea, we act as your local representative, manage interactions with the MFDS and NIDS, and prepare your technical dossier for submission. Our experts can help you navigate the proposed 'one-stop' certification process for Class II devices, ensuring your submission is complete and accurate to maximize the benefits of the accelerated timeline. We combine local expertise with advanced AI to get your products to market faster. Visit https://pureglobal.com, email us at info@pureglobal.com, or explore our free AI tools and device database at https://pureglobal.ai.
    続きを読む 一部表示
    5 分
  • FDA IDE Electronic Submission Guidance: Preparing for the New Template

    FDA IDE Electronic Submission Guidance: Preparing for the New Template
    2026/11/02
    This episode covers the US FDA's new draft guidance, released on October 27, 2026, which introduces a standardized 'Electronic Submission Template for Investigational Device Exemption (IDE) Applications.' We discuss the FDA's goals of improving submission consistency and review efficiency, the key components of the proposed template, and who will be most affected. We also highlight the critical December 28, 2026, deadline for industry feedback and provide practical steps for regulatory and clinical teams to prepare for this upcoming change. Key Questions: - What is the new FDA draft guidance on IDE electronic submissions? - Why is the FDA introducing a standardized template for IDE applications? - Who will be most affected by this proposed change? - What is the critical deadline for providing feedback to the FDA on this draft guidance? - How does the new template aim to improve the IDE review process? - What are the key sections of the proposed electronic submission template? - What practical steps should regulatory teams take in response to this draft guidance? - How can sponsors prepare their internal processes for this new format? Sources: - https://www.federalregister.gov/documents/2026/10/28/2026-23501/electronic-submission-template-for-investigational-device-exemption-ide-applications-draft - https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-submission-template-investigational-device-exemption-ide-applications - https://www.fda.gov/medical-devices/news-events-medical-devices/cdrh-new-news-and-updates How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech companies access global markets faster. Our experts can help you navigate the new FDA IDE submission requirements, develop an efficient regulatory strategy for your US clinical trials, and compile your technical dossier using advanced AI tools. We act as your local representative and ensure your submissions are complete and compliant to minimize delays. For support with your market access strategy, visit us at https://pureglobal.com or contact us at info@pureglobal.com. Explore our free AI regulatory tools and device database at https://pureglobal.ai.
    続きを読む 一部表示
    5 分
  • Brazil ANVISA Medical Device Recall October 2026: Rota-Strip, CLOSURERFS, and BD Catheters

    Brazil ANVISA Medical Device Recall October 2026: Rota-Strip, CLOSURERFS, and BD Catheters
    2026/11/01
    Brazil's health authority, ANVISA, announced on October 23, 2026, the suspension and recall of several medical devices due to significant compliance failures. This episode details the specific products affected, including the Rota-Strip diagnostic test, the CLOSURERFS radiofrequency ablation stylet, and certain lots of the BD Angioccath catheter. We analyze the reasons behind each recall—from unsatisfactory test results to manufacturing non-compliance—and discuss the broader implications for manufacturers. The focus is on the critical importance of adhering to Good Manufacturing Practices (GMP) and maintaining a robust post-market surveillance system to ensure continued market access in Brazil. Key Questions: - What specific medical devices did ANVISA recall in its October 2026 announcement? - Why was the Rota-Strip diagnostic test suspended from the Brazilian market? - What manufacturing non-compliance led to the recall of Covidien's CLOSURERFS stylet? - Which lots of the BD Angioccath catheter were recalled and what was the associated risk? - What do these enforcement actions reveal about ANVISA's approach to post-market surveillance? - How does this event impact GMP requirements for medical device manufacturers in Brazil? - What are the essential components of an effective post-market surveillance plan for the Brazilian market? - What immediate, practical steps should regulatory and quality teams take in response to this news? Sources: - https://www.portal.afya.com.br/noticias/anvisa-suspende-e-recolhe-dispositivos-medicos-irregulares - https://conexaogeral.com.br/anvisa-suspende-teste-para-rotavirus-e-determina-recolhimento-de-dispositivos-medicos/ How Pure Global can help: Pure Global provides comprehensive regulatory consulting to help MedTech and IVD companies navigate complex markets like Brazil. Our experts offer end-to-end support, from developing a regulatory strategy and compiling technical dossiers to securing ANVISA registration and GMP certification. We also act as your Brazil Registration Holder and provide post-market surveillance services to ensure ongoing compliance. With our deep local expertise and advanced AI tools, we streamline the path to market access, helping you launch your products faster and maintain them compliantly. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.
    続きを読む 一部表示
    5 分
  • Brazil ANVISA Recognized Technical Standards: New Lists for Medical Devices

    Brazil ANVISA Recognized Technical Standards: New Lists for Medical Devices
    2026/10/31
    On October 22, 2026, Brazil's ANVISA published three new workbooks of recognized technical standards for medical devices. This episode explores the three new lists—transversal standards, orthopedic implantable materials, and health-use materials—and explains how manufacturers can voluntarily use them to create a presumption of conformity with Brazil's essential safety and performance requirements. We discuss how leveraging these standards can streamline the preparation and review of technical documentation, simplifying market access for new and existing products. Key Questions: - What are ANVISA's newly recognized technical standards published on October 22, 2026? - How do these standards relate to Brazil's core medical device regulation, RDC 751/2022? - What are the three new workbooks of standards and what do they cover? - How can using these voluntary standards create a 'presumption of conformity'? - Which types of medical devices are most affected by the new lists? - What is the difference between the 'transversal,' 'orthopedic materials,' and 'health-use materials' lists? - What practical steps should regulatory and quality teams take in response to this announcement? - Can declaring conformity to these standards help speed up the review of a technical dossier in Brazil? Sources: - https://www.pure-global.com/news/brazil-anvisa-publishes-three-recognized-device-standards-lists How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech companies achieve and maintain market access in over 30 countries, including Brazil. Our experts can help you navigate ANVISA's requirements, leverage recognized technical standards to build a robust technical dossier, and act as your Brazil Registration Holder. We combine local expertise with advanced AI tools to streamline submission preparation, post-market surveillance, and regulatory intelligence, helping you get to market faster. To learn more about our services, visit https://pureglobal.com, contact us at info@pureglobal.com, or explore our free AI tools and device database at https://pureglobal.ai.
    続きを読む 一部表示
    6 分
  • SFDA Medical Device Validity Extension: New Emergency Guidance MDS-G003

    SFDA Medical Device Validity Extension: New Emergency Guidance MDS-G003
    2026/10/30
    The Saudi Food and Drug Authority (SFDA) has issued emergency guidance, MDS-G003, on October 22, 2026, creating a new process for the temporary validity extension of medical device registrations during critical national shortages. This episode details the conditions under which manufacturers can request an extension, the formal submission process, and the implications for both manufacturers and their local Authorized Representatives. We outline the specific criteria required by the SFDA, including the device's essentiality and the absence of viable alternatives, and provide practical steps for regulatory and quality teams to prepare for potential supply chain disruptions. Key Questions: - What is the SFDA's new emergency guidance MDS-G003 for medical devices? - Under what specific circumstances can a medical device registration validity be extended in Saudi Arabia? - Who is eligible to apply for a temporary registration extension? - What conditions must be met to prove a critical national shortage to the SFDA? - What is the formal process for submitting a validity extension request? - How does this guidance impact manufacturers and their Saudi Authorized Representatives? - What documentation is required to support an extension application? - How can companies proactively prepare for potential shortages in the Saudi market? - What are the risks of not having a strategy for registration renewals? Sources: - https://regnext.com/daily-briefing/middle-east-africa-daily-briefing-22-oct-2026/ How Pure Global can help: Pure Global provides comprehensive regulatory consulting to help MedTech and IVD companies access global markets faster. Our experts offer end-to-end support, from developing regulatory strategies and compiling technical dossiers to acting as your in-country representative in over 30 markets, including Saudi Arabia. We help you navigate complex requirements like the SFDA's MDS-G003 guidance, ensuring you can maintain market presence even during unforeseen challenges. Leverage our local expertise and advanced AI tools to streamline your registration, renewal, and post-market surveillance activities. Visit us at https://pureglobal.com, contact us at info@pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.
    続きを読む 一部表示
    5 分
  • UK MHRA Indefinite CE Marking Recognition: A New Era for Great Britain Market Access

    UK MHRA Indefinite CE Marking Recognition: A New Era for Great Britain Market Access
    2026/10/29
    The UK MHRA has announced a major policy shift: it will indefinitely recognize CE-marked medical devices that comply with the EU's MDR and IVDR. This episode breaks down the October 21, 2026 announcement, explaining what the removal of the 2030 UKCA deadline means for manufacturers. We cover the continued, critical role of the UK Responsible Person (UKRP), the status of the UKCA mark as a parallel pathway, and the pending legislation needed to formalize this change. Tune in for practical steps your regulatory team should take now to leverage this simplified route to the Great Britain market. Key Questions: - What does the MHRA's indefinite recognition of CE marking mean for my device? - Is the 2030 deadline for UKCA marking officially gone? - Do I still need a UK Responsible Person (UKRP) to sell in Great Britain? - How does this policy affect devices certified under the EU MDR versus the old directives? - What is the status of the UKCA mark now? - When will this policy announcement officially become law? - What practical steps should my regulatory team take right now? - Does this change apply to Northern Ireland? Sources: - https://www.gov.uk/government/news/uk-government-announces-indefinite-recognition-of-ce-marking-for-medical-devices - https://citeline.informa.com/regulatory/uk-recommends-indefinite-ce-marking-for-devices-in-great-britain - https://www.digitalhealth.net/2026/10/ce-marked-medical-devices-granted-indefinite-recognition/ - https://www.hilldickinson.com/insights/articles/medical-devices-update-uk-confirms-indefinite-recognition-ce-marking How Pure Global can help: Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative in over 30 markets, including providing UK Responsible Person (UKRP) services to ensure your compliance in Great Britain. Our experts develop efficient regulatory strategies and use advanced AI to compile and manage technical dossiers, helping you get to market faster. Whether you're a startup or a multinational, we provide the strategic support you need for expansion. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.
    続きを読む 一部表示
    6 分